keyword
MENU ▼
Read by QxMD icon Read
search

Bupropion

keyword
https://www.readbyqxmd.com/read/29352029/dissociable-temporal-effects-of-bupropion-on-behavioural-measures-of-emotional-and-reward-processing-in-depression
#1
Annabel E L Walsh, Michael Browning, Wayne C Drevets, Maura Furey, Catherine J Harmer
Antidepressants remediate negative biases in emotional processing early in treatment, prior to mood improvement. However, the effects on reward processing potentially relevant to the treatment of anhedonia are less clear. Here we investigate the early and sustained effects of the dopamine and noradrenaline reuptake inhibitor bupropion on behavioural measures of emotional and reward processing in currently depressed individuals. Forty-six currently depressed patients and 42 healthy controls participated in a repeated measures study, during which open-label bupropion was administered to only the patient group over a six week period without a placebo group...
March 19, 2018: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
https://www.readbyqxmd.com/read/29344340/assessment-and-management-of-sexual-dysfunction-in-the-context-of-depression
#2
REVIEW
Pratap R Chokka, Jeffrey R Hankey
Sexual dysfunction (SD) is pervasive and underreported, and its effects on quality of life are underestimated. Due in part to its bidirectional relationship with depression, SD can be difficult to diagnose; it is also a common side effect of many antidepressants, leading to treatment noncompliance. While physicians often count on patients to spontaneously report SD, treatment is optimized when the clinician instead performs a thorough assessment of sexual functioning before and during drug therapy using a standardized questionnaire such as the Arizona Sexual Experiences Scale (ASEX)...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29334200/comparative-effectiveness-of-antidepressant-medication-versus-psychological-intervention-on-depression-symptoms-in-women-with-infertility-and-sexual-dysfunction
#3
Hajar Pasha, Zahra Basirat, Mahbobeh Faramarzi, Farzan Kheirkhah
Background: Fertility loss is considered as a challenging experience. This study was conducted to compare the effectiveness of antidepressant medication and psychological intervention on depression symptoms in women with infertility and sexual dysfunctions (SD). MATERIALS AND METHODS: This randomized, controlled clinical trial study was completed from December 2014 to June 2015 in Babol, Iran. Of the 485 participants, 93 were randomly assigned in a 1:1:1 ratio to psychosexual therapy (PST), bupropion extended-release (BUP ER) at a dose of 150 mg/d, and control (no intervention) groups...
April 2018: International Journal of Fertility & Sterility
https://www.readbyqxmd.com/read/29332813/fast-and-easy-extraction-of-antidepressants-from-whole-blood-using-ionic-liquids-as-extraction-solvent
#4
Marieke De Boeck, Lisa Dubrulle, Wim Dehaen, Jan Tytgat, Eva Cuypers
This study aims to prove that ionic liquids (ILs) can be used as extraction solvents in a liquid-liquid microextraction, coupled to LC-MS/MS, for the quantification of a large group of antidepressants in whole blood samples. The sample preparation procedure consisted of adding 1.0mL aqueous buffer pH 3.0 and 60µL of IL (1-butyl-3-methylimidazolium hexafluorophosphate) to 1.0mL whole blood. Subsequently, a 5-min rotary mixing step was performed followed by centrifugation. The lower IL phase was collected, diluted 1:10 in methanol and 10µL was injected into the LC-MS/MS...
April 1, 2018: Talanta
https://www.readbyqxmd.com/read/29313652/lung-cancer-smoking-cessation
#5
Kelly M Latimer
Smoking cessation for patients who smoke should be a top priority for physicians. Nicotine dependence should be considered a chronic disease, with the expectation that relapse is normal. The US Preventive Services Task Force (USPSTF) recommends that physicians screen all adults for tobacco use, advise them to stop using tobacco, and provide behavioral interventions and Food and Drug Administration-approved pharmacotherapy for cessation to adults who use tobacco. It also recommends use of the 5 As (ie, Ask, Advise, Assess, Assist, Arrange) in discussing tobacco use with patients...
January 2018: FP Essentials
https://www.readbyqxmd.com/read/29305933/effects-of-weight-loss-medications-on-cardiometabolic-risk-profiles-a-systematic-review-and-network-meta-analysis
#6
Rohan Khera, Ambarish Pandey, Apoorva K Chandar, Mohammad H Murad, Larry J Prokop, Ian J Neeland, Jarett Berry, Michael Camilleri, Siddharth Singh
BACKGROUND & AIMS: We performed a systematic review and network meta-analysis to evaluate the overall and comparative effects of weight-loss medications, approved by the Food and Drug Administration (FDA) for long-term use, on cardiometabolic risk profiles of obese adults. METHODS: We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of FDA-approved weight loss medications (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide), administered to obese adults for 1 year or more, compared with placebo or another active agent...
January 3, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29301630/obesity-pathophysiology-and%C3%A2-management
#7
REVIEW
Kishore M Gadde, Corby K Martin, Hans-Rudolf Berthoud, Steven B Heymsfield
Obesity continues to be among the top health concerns across the globe. Despite our failure to contain the high prevalence of obesity, we now have a better understanding of its pathophysiology, and how excess adiposity leads to type 2 diabetes, hypertension, and cardiovascular disease. Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due to difficulty with adherence as well as physiological and neurohormonal adaptation of the body in response to weight loss...
January 2, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29290899/a-lazarus-effect-a-case-report-of-bupropion-overdose-mimicking-brain-death
#8
Douglas Stranges, Alan Lucerna, James Espinosa, Neveen Malik, Marc Mongeau, Kelly Schiers, Syed Omar Shah, Joan Wiley, Philip Willsie
No abstract text is available yet for this article.
2018: World Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29287757/efficacy-of-adjuvant-weight-loss-medication-after-bariatric-surgery
#9
Zubaidah Nor Hanipah, Elie C Nasr, Emre Bucak, Philip R Schauer, Ali Aminian, Stacy A Brethauer, Derrick Cetin
BACKGROUND: Some patients do not achieve optimal weight loss or regain weight after bariatric surgery. In this study, we aimed to determine the effectiveness of adjuvant weight loss medications after surgery for this group of patients. SETTING: An academic medical center. METHODS: Weight changes of patients who received weight loss medications after bariatric surgery from 2012 to 2015 at a single center were studied. RESULTS: Weight loss medications prescribed for 209 patients were phentermine (n = 156, 74...
January 2018: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/29281040/effectiveness-of-pharmaceutical-smoking-cessation-aids-in-a-nationally-representative-cohort-of-american-smokers
#10
Eric C Leas, John P Pierce, Tarik Benmarhnia, Martha M White, Madison L Noble, Dennis R Trinidad, David R Strong
Background: Despite strong efficacy in randomized trials, the population effectiveness of pharmaceutical aids in long-term smoking cessation is lacking, possibly because of confounding (factors that are associated with both pharmaceutical aid use and difficulty quitting). Matching techniques in longitudinal studies can remove this confounding bias. Methods: Using the nationally representative Tobacco Use Supplement to the Current Population Survey (TUS-CPS), we assessed the effectiveness of medications to aid quitting among baseline adult smokers who attempted to quit prior to one year of follow-up in two longitudinal studies: 2002-2003 and 2010-2011...
December 21, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29250815/current-and-emerging-pharmacotherapies-for-cessation-of-tobacco-smoking
#11
Nieves Gómez-Coronado, Adam J Walker, Michael Berk, Seetal Dodd
Tobacco use disorder is a chronic illness. With its high comorbidity rate, it is a major cause of years of life lost or years lived with disability; however, is also considered the most preventable cause of death in developed countries. Since the development of nicotine replacement therapy (NRT) in 1978, treatment options have continued to evolve and expand. Despite this, currently available treatments remain insufficient, with less than 25% of smokers remaining abstinent after one year after treatment. In this article, we review existing and emerging smoking cessation pharmacotherapies, affording a special emphasis on the most promising agents that are currently being investigated...
December 17, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29223599/pharmacological-intervention-and-abstinence-in-smokers-undergoing-cessation-treatment-a-psychophysiological-study
#12
Yong Cui, Jeffrey M Engelmann, Jonathan Xian, Jennifer A Minnix, Cho Y Lam, Maher Karam-Hage, Paul M Cinciripini, Jason D Robinson
As a composite concept, negative affect comprises various aversive emotional experiences, such as irritability and nervousness. It is a critical motivational factor that helps maintain smoking behavior, and contributes significantly to smoking cessation failure as a core withdrawal symptom. Prior research has indicated an important role of nicotinic mechanisms in negative affect processing. The most effective smoking cessation medication, varenicline, targets nicotinic acetylcholine receptors (nAChRs) as a partial agonist, while another first-line cessation medication, bupropion, has shown antagonistic effects on nAChRs...
December 6, 2017: International Journal of Psychophysiology
https://www.readbyqxmd.com/read/29222923/co-administration-of-low-dose-naltrexone-and-bupropion-reduces-alcohol-drinking-in-alcohol-preferring-p-rats
#13
Emily R Nicholson, Julian E Dilley, Janice C Froehlich
BACKGROUND: This study examined whether combining naltrexone (NTX) with bupropion (BUP) is more effective in reducing alcohol drinking in alcohol-preferring (P) rats with a genetic predisposition toward high voluntary alcohol intake than is either drug alone. METHODS: Alcohol-experienced, adult, male, alcohol-preferring (P) rats were fed NTX alone in a dose of 10.0 mg/kg BW, BUP alone in a dose of 10.0 mg/kg BW, BUP alone in a dose of 20.0 mg/kg BW, NTX (10.0 mg/kg BW) + BUP (10...
December 9, 2017: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29220524/brain-responses-to-cigarette-related-and-emotional-images-in-smokers-during-smoking-cessation-no-effect-of-varenicline-or-bupropion-on-the-late-positive-potential
#14
Francesco Versace, Elise M Stevens, Jason D Robinson, Yong Cui, Menton M Deweese, Jeffrey M Engelmann, Charles E Green, Maher Karam-Hage, Cho Y Lam, Jennifer A Minnix, David W Wetter, Paul M Cinciripini
Introduction: Varenicline and bupropion are two effective smoking cessation pharmacotherapies. Researchers have hypothesized that they might be effective, in part, because they reduce cue reactivity and cue-induced cravings. Here, we used event-related potentials (ERPs) to directly measure brain responses to cigarette-related and other motivationally relevant images during a pharmacologically aided quit attempt. Methods: Smokers involved in a 12-week placebo-controlled double-blind clinical trial of smoking cessation medications (varenicline, bupropion, placebo) took part in the study...
December 6, 2017: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/29215304/weight-gain-changes-in-patients-with-aripiprazole-monotherapy-compared-with-aripiprazole-antidepressant-polypharmacy-in-an-outpatient-sample
#15
Charles Nguyen, Andrei Novac, Jessica Hazen, Pamela Howard, Ryan Tieu, Robert G Bota
OBJECTIVE: This study seeks to evaluate the weight gain effect within a community-based population of patients with diagnoses of depression, mood disorder, and schizophrenia receiving aripiprazole over a period of at least 6 months. METHOD: The four million members of Kaiser Permanente of Southern California (KPSC) were queried for a four-year period between January 1, 2010 and December 31, 2013. The initial cohort comprised 25,682 KPSC members who received at least one dispense of aripiprazole...
December 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29212337/-status-of-pharmacotherapy-in-current-care-of-obese
#16
Petr Sucharda
Weight loss drugs or anti-obesity drugs have a long history but are still far from being successful. Only in two last decades have the drugs been launched, which, when appropriately indicated, may be significantly beneficial to patients in need of weight loss as they are comparably effective to intensive programs to promote changes in eating habits and lifestyles. The combination naltrexone/bupropion is promising for food intake control including the reward mechanism, but the experience with its use has only been short-term...
2017: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/29202894/failure-to-detect-the-action-of-antidepressants-in-the-forced-swim-test-in-swiss-mice
#17
Patrick R Suman, Nathalia Zerbinatti, Lais Cristina Theindl, Karolina Domingues, Cilene Lino de Oliveira
OBJECTIVE: The aims of this study were to replicate previously published experiments and to modify the protocol to detect the effects of chronic antidepressant treatment in mice. METHODS: Male Swiss mice (n=6-8/group) housed in reversed light/dark cycle were randomly assigned into receive vehicle (10% sucrose), sub-effective doses (1 and 3 mg/kg) or effective doses (10 and 30 mg/kg) of bupropion, desipramine, and fluoxetine and a candidate antidepressant, sodium butyrate (1-30 mg/kg) per gavage (p...
December 5, 2017: Acta Neuropsychiatrica
https://www.readbyqxmd.com/read/29198512/understanding-the-role-of-serotonin-in-female-hypoactive-sexual-desire-disorder-and-treatment-options
#18
REVIEW
Harry A Croft
BACKGROUND: The neurobiology of sexual response is driven in part by dopamine and serotonin-the former modulating excitatory pathways and the latter regulating inhibitory pathways. Neurobiological underpinnings of hypoactive sexual desire disorder (HSDD) are seemingly related to overactive serotonin activity that results in underactive dopamine activity. As such, pharmacologic agents that decrease serotonin, increase dopamine, or some combination thereof, have therapeutic potential for HSDD...
December 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29196725/pharmacogenetic-study-of-seven-polymorphisms-in-three-nicotinic-acetylcholine-receptor-subunits-in-smoking-cessation-therapies
#19
Giulia Pintarelli, Antonella Galvan, Paolo Pozzi, Sara Noci, Giovanna Pasetti, Francesca Sala, Ugo Pastorino, Roberto Boffi, Francesca Colombo
Smoking-cessation therapy reduces the risk of smoking-related diseases, but is successful only in a fraction of smokers. There is growing evidence that genetic variations in nicotinic acetylcholine receptor (nAChR) subunits influence the risk of nicotine dependence and the ability to quit smoking. To investigate the role of polymorphisms in nAChR genes on smoking quantity and the outcome of smoking-cessation therapies, we carried out an association study on 337 smokers who underwent pharmacotherapy with varenicline, bupropion, nicotine replacement therapy (NRT) alone, or NRT plus bupropion...
December 1, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29189941/vortioxetine-clinical-pharmacokinetics-and-drug-interactions
#20
REVIEW
Grace Chen, Astrid-Maria Højer, Johan Areberg, George Nomikos
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses. The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing. The mean absolute oral bioavailability of vortioxetine is 75%. No food effect on pharmacokinetics was observed...
November 30, 2017: Clinical Pharmacokinetics
keyword
keyword
11519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"